Stephen Mahoney

Stephen Mahoney

Former President, Chief Financial and Operating OfficeratDianthus Therapeutics, Inc. /DE/· In proxies 2022–2023

Pay in FY2023+48% from the year before · Dianthus Therapeutics, Inc. /DE/ stock +64.6% the same year

Stephen Mahoney was paid $1.7M in FY2023 (Dec), up 48%. Dianthus Therapeutics, Inc. /DE/ stock rose 64.6% that year.

Pay$100 in the stock at the end of FY21 → $15
Pay is from the Summary Compensation Table of each Dianthus Therapeutics, Inc. /DE/ proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Dianthus Therapeutics, Inc. /DE/Public company · 4 yr
    • Former President, Chief Financial and Operating Officer2022 – Present · 4 yrStock in role +11%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?